Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human Remove Human filter Veterinary (8) Apply Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Referrals Remove Referrals filter Summaries of opinion (16) Apply Summaries of opinion filter Withdrawn applications (13) Apply Withdrawn applications filter Paediatric investigation plans (178) Apply Paediatric investigation plans filter Orphan designations (106) Apply Orphan designations filter Direct healthcare professional communication (9) Apply Direct healthcare professional communication filter

Product number

Patient safety

Yes (6) Apply Yes filter

Authorisation status

Authorised (332) Apply Authorised filter Withdrawn (33) Apply Withdrawn filter

ATC code

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

Referral name

Referral status

European Commission final decision (16) Apply European Commission final decision filter Opinion provided by Committee for Medicinal Products for Human Use (1) Apply Opinion provided by Committee for Medicinal Products for Human Use filter

Referral safety status

Yes (6) Apply Yes filter

Referral type

Article 20 procedures (12) Apply Article 20 procedures filter Article 31 referrals (5) Apply Article 31 referrals filter

Referral reference number

Referral decision making model

PRAC-CHMP-EC (15) Apply PRAC-CHMP-EC filter

Referral authorisation model

Centrally and nationally authorised products (mixed) (4) Apply Centrally and nationally authorised products (mixed) filter Centrally authorised product(s) (12) Apply Centrally authorised product(s) filter

Referral PRAC recommendation

Risk minimisation measures (12) Apply Risk minimisation measures filter Suspension (2) Apply Suspension filter

Referral procedure start date

From:

To:

Referral PRAC recommendation date

From:

To:

Decision date

From:

To:

Medicine type

Accelerated assessment Remove Accelerated assessment filter Additional monitoring Remove Additional monitoring filter Conditional approval Remove Conditional approval filter Biosimilar (70) Apply Biosimilar filter Exceptional circumstances (37) Apply Exceptional circumstances filter Generic (252) Apply Generic filter Orphan medicine (128) Apply Orphan medicine filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

382 results

Remove all filtersRemove all filters

Medicine European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Referrals Remove Referrals filter

Categories Human Remove Human filter

Medicine type Accelerated assessment Remove Accelerated assessment filter Additional monitoring Remove Additional monitoring filter Conditional approval Remove Conditional approval filter

Sort by

List item

Human medicine European public assessment report (EPAR): Mvabea (updated)

Recombinant Modified Vaccinia Ankara Bavarian Nordic Virus encoding the: Ebola virus Zaire (ZEBOV) Mayinga strain glycoprotein (GP); Ebola virus Sudan Gulu strain GP; Ebola virus Taï Forest strain nucleoprotein and the Marburg virus Musoke strain GP, Hemorrhagic Fever, Ebola
Date of authorisation: 01/07/2020, , , Authorised, Last updated: 24/11/2020
List item

Human medicine European public assessment report (EPAR): Lamzede (updated)

velmanase alfa, alpha-Mannosidosis
Date of authorisation: 23/03/2018, , , , Revision: 3, Authorised, Last updated: 24/11/2020
List item

Human medicine European public assessment report (EPAR): Alofisel (updated)

darvadstrocel, Rectal Fistula
Date of authorisation: 23/03/2018, , , Revision: 5, Authorised, Last updated: 24/11/2020
List item

Human medicine European public assessment report (EPAR): Orkambi (updated)

Lumacaftor, ivacaftor, Cystic Fibrosis
Date of authorisation: 18/11/2015, , Revision: 23, Authorised, Last updated: 23/11/2020
List item

Human medicine European public assessment report (EPAR): Skyrizi (updated)

Risankizumab, Psoriasis
Date of authorisation: 26/04/2019, , Revision: 4, Authorised, Last updated: 23/11/2020
List item

Human medicine European public assessment report (EPAR): Vyndaqel (updated)

tafamidis, Amyloidosis
Date of authorisation: 16/11/2011, , , , Revision: 17, Authorised, Last updated: 23/11/2020
List item

Human medicine European public assessment report (EPAR): Veklury (updated)

remdesivir, Coronavirus Infections
Date of authorisation: 03/07/2020, , , Revision: 1, Authorised, Last updated: 20/11/2020
List item

Human medicine European public assessment report (EPAR): Imraldi (updated)

adalimumab, Hidradenitis Suppurativa, Psoriasis, Crohn Disease, Uveitis, Arthritis, Rheumatoid, Arthritis, Colitis, Ulcerative, Spondylitis, Ankylosing, Arthritis, Psoriatic
Date of authorisation: 24/08/2017, , , Revision: 13, Authorised, Last updated: 20/11/2020
List item

Human medicine European public assessment report (EPAR): Darzalex (updated)

Daratumumab, Multiple Myeloma
Date of authorisation: 20/05/2016, , , , Revision: 14, Authorised, Last updated: 20/11/2020
List item

Human medicine European public assessment report (EPAR): Mysimba (updated)

bupropion hydrochloride, naltrexone hydrochloride, Obesity, Overweight
Date of authorisation: 26/03/2015, , Revision: 17, Authorised, Last updated: 20/11/2020
List item

Human medicine European public assessment report (EPAR): Ondexxya (updated)

andexanet alfa, Drug-Related Side Effects and Adverse Reactions
Date of authorisation: 26/04/2019, , , Revision: 6, Authorised, Last updated: 20/11/2020
List item

Human medicine European public assessment report (EPAR): Cablivi (updated)

Caplacizumab, Purpura, Thrombotic Thrombocytopenic
Date of authorisation: 30/08/2018, , , Revision: 4, Authorised, Last updated: 20/11/2020
List item

Human medicine European public assessment report (EPAR): Myalepta (updated)

Metreleptin, Lipodystrophy, Familial Partial
Date of authorisation: 29/07/2018, , , , Revision: 4, Authorised, Last updated: 20/11/2020
List item

Human medicine European public assessment report (EPAR): Zavicefta (updated)

avibactam sodium, ceftazidime pentahydrate, Pneumonia, Bacterial, Soft Tissue Infections, Pneumonia, Urinary Tract Infections, Gram-Negative Bacterial Infections
Date of authorisation: 23/06/2016, , Revision: 9, Authorised, Last updated: 20/11/2020
List item

Human medicine European public assessment report (EPAR): Polivy (updated)

polatuzumab vedotin, Lymphoma, B-Cell
Date of authorisation: 16/01/2020, , , , Revision: 1, Authorised, Last updated: 19/11/2020
List item

Human medicine European public assessment report (EPAR): Gilenya (updated)

fingolimod hydrochloride , Multiple Sclerosis
Date of authorisation: 17/03/2011, , , Revision: 26, Authorised, Last updated: 19/11/2020
List item

Human medicine European public assessment report (EPAR): Ofev (updated)

nintedanib, Idiopathic Pulmonary Fibrosis
Date of authorisation: 14/01/2015, , Revision: 15, Authorised, Last updated: 18/11/2020
List item

Human medicine European public assessment report (EPAR): Flucelvax Tetra (updated)

Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of the following strains: A/Hawaii/70/2019 (H1N1)pdm09-like strain (A/Nebraska/14/2019, wild type); A/Hong Kong/45/2019 (H3N2)-like strain (A/Delaware/39/2019, wild type); B/Washington/02/2019-like strain (B/Darwin/7/2019, wild type); B/Phuket/3073/2013-like strain (B/Singapore/INFTT-16-0610/2016, wild type), Influenza, Human
Date of authorisation: 12/12/2018, , Revision: 6, Authorised, Last updated: 18/11/2020
List item

Human medicine European public assessment report (EPAR): Keytruda (updated)

Pembrolizumab, Melanoma, Hodgkin Disease, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 17/07/2015, , Revision: 29, Authorised, Last updated: 17/11/2020
List item

Human medicine European public assessment report (EPAR): Glyxambi (updated)

empagliflozin, linagliptin, Diabetes Mellitus, Type 2
Date of authorisation: 11/11/2016, , Revision: 11, Authorised, Last updated: 16/11/2020
List item

Human medicine European public assessment report (EPAR): Zirabev (updated)

bevacizumab, Colorectal Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms
Date of authorisation: 14/02/2019, , , Revision: 5, Authorised, Last updated: 16/11/2020
List item

Human medicine European public assessment report (EPAR): Equidacent (updated)

bevacizumab, Colorectal Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
Date of authorisation: 24/09/2020, , Revision: 1, Authorised, Last updated: 16/11/2020
List item

Human medicine European public assessment report (EPAR): Besponsa (updated)

inotuzumab ozogamicin, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Date of authorisation: 28/06/2017, , , Revision: 7, Authorised, Last updated: 16/11/2020
List item

Human medicine European public assessment report (EPAR): Isentress (updated)

Raltegravir, HIV Infections
Date of authorisation: 19/12/2007, , Revision: 37, Authorised, Last updated: 16/11/2020
List item

Human medicine European public assessment report (EPAR): Talzenna (updated)

talazoparib, Breast Neoplasms
Date of authorisation: 20/06/2019, , Revision: 3, Authorised, Last updated: 13/11/2020